Marianne Manchester

List of Publications by Year
in descending order

75 papers	6,821 citations	50276 46 h-index	79698 73 g-index
76 all docs	76 docs citations	76 times ranked	6963 citing authors

#	Article	IF	Citations
1	Single-Point Mutations in QÎ² Virus-like Particles Change Binding to Cells. Biomacromolecules, 2021, 22, 3332-3341.	5.4	14
2	Metabolomics. Advances in Virus Research, 2017, 98, 57-81.	2.1	51
3	Virus-Based Nanoparticles as Versatile Nanomachines. Annual Review of Virology, 2015, 2, 379-401.	6.7	136
4	Alterations in Spinal Cord Metabolism during Treatment of Neuropathic Pain. Journal of NeuroImmune Pharmacology, 2015, 10, 396-401.	4.1	8
5	Localization of gadolinium-loaded CPMV to sites of inflammation during central nervous system autoimmunity. Journal of Materials Chemistry B, 2013, 1, 5256.	5.8	6
6	Endocytic Uptake Pathways Utilized by CPMV Nanoparticles. Molecular Pharmaceutics, 2013, 10, 26-32.	4.6	52
7	Readily Accessible Fluorescent Probes for Sensitive Biological Imaging of Hydrogen Peroxide. ChemBioChem, 2013, 14, 593-598.	2.6	26
8	Lysine Addressability and Mammalian Cell Interactions of Bacteriophage Î» Procapsids. Biomacromolecules, 2013, 14, 4169-4176.	5.4	13
9	A View from Above: Cloud Plots to Visualize Global Metabolomic Data. Analytical Chemistry, 2013, 85, 798-804.	6.5	85
10	Guiding plant virus particles to integrin-displaying cells. Nanoscale, 2012, 4, 3698.	5.6	50
11	Differential Uptake of Chemically Modified Cowpea Mosaic Virus Nanoparticles in Macrophage Subpopulations Present in Inflammatory and Tumor Microenvironments. Biomacromolecules, 2012, 13, 3320-3326.	5.4	19
12	Interaction of cowpea mosaic virus nanoparticles with surface vimentin and inflammatory cells in atherosclerotic lesions. Nanomedicine, 2012, 7, 877-888.	3.3	34
13	Metabolomics implicates altered sphingolipids in chronic pain of neuropathic origin. Nature Chemical Biology, 2012, 8, 232-234.	8.0	183
14	Delayed Toxicity Associated with Soluble Anthrax Toxin Receptor Decoy-Ig Fusion Protein Treatment. PLoS ONE, 2012, 7, e34611.	2.5	13
15	Inhibition of fatty acid metabolism ameliorates disease activity in an animal model of multiple sclerosis. Scientific Reports, 2011, 1, 79.	3.3	81
16	Transferrin-mediated targeting of bacteriophage HK97 nanoparticles into tumor cells. Nanomedicine, 2011, 6, 55-68.	3.3	52
17	Cowpea mosaic virus nanoparticles target surface vimentin on cancer cells. Nanomedicine, 2011, 6, 351-364.	3.3	107
18	Multivalent Display of Proteins on Viral Nanoparticles Using Molecular Recognition and Chemical Ligation Strategies. Biomacromolecules, 2011, 12, 2293-2301.	5.4	49

#	Article	IF	Citations
19	Viral nanoparticles and virusâ€like particles: platforms for contemporary vaccine design. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 2011, 3, 174-196.	6.1	189
20	Chemically modified viruses: principles and applications. Current Opinion in Chemical Biology, 2010, 14, 810-817.	6.1	34
21	Intravital imaging of embryonic and tumor neovasculature using viral nanoparticles. Nature Protocols, 2010, 5, 1406-1417.	12.0	129
22	Potato Virus X as a Novel Platform for Potential Biomedical Applications. Nano Letters, 2010, 10, 305-312.	9.1	99
23	Labeling Live Cells by Copper-Catalyzed Alkyneâ^'Azide Click Chemistry. Bioconjugate Chemistry, 2010, 21, 1912-1916.	3.6	347
24	Detection of Carbohydrates and Steroids by Cation-Enhanced Nanostructure-Initiator Mass Spectrometry (NIMS) for Biofluid Analysis and Tissue Imaging. Analytical Chemistry, 2010, 82, 121-128.	6.5	94
25	Hydrazone Ligation Strategy to Assemble Multifunctional Viral Nanoparticles for Cell Imaging and Tumor Targeting. Nano Letters, 2010, 10, 1093-1097.	9.1	144
26	The Use of Viruses in Biomedical Nanotechnology. , 2010, , 289-311.		1
27	Efficient Neutralization of Antibody-Resistant Forms of Anthrax Toxin by a Soluble Receptor Decoy Inhibitor. Antimicrobial Agents and Chemotherapy, 2009, 53, 1210-1212.	3.2	27
28	Anti-toxin antibodies in prophylaxis and treatment of inhalation anthrax. Future Microbiology, 2009, 4, 35-43.	2.0	46
29	Endothelial Targeting of Cowpea Mosaic Virus (CPMV) via Surface Vimentin. PLoS Pathogens, 2009, 5, e1000417.	4.7	160
30	Viral nanoparticles associate with regions of inflammation and blood brain barrier disruption during CNS infection. Journal of Neuroimmunology, 2009, 211, 66-72.	2.3	49
31	Tomato bushy stunt virus (TBSV), a versatile platform for polyvalent display of antigenic epitopes and vaccine design. Virology, 2009, 388, 185-190.	2.4	30
32	PEGylated Viral Nanoparticles for Biomedicine: The Impact of PEG Chain Length on VNP Cell Interactions In Vitro and Ex Vivo. Biomacromolecules, 2009, 10, 784-792.	5.4	128
33	Response and Recovery in the Plasma Metabolome Tracks the Acute LCMV-Induced Immune Response. Journal of Proteome Research, 2009, 8, 3578-3587.	3.7	32
34	Buckyballs Meet Viral Nanoparticles: Candidates for Biomedicine. Journal of the American Chemical Society, 2009, 131, 17093-17095.	13.7	119
35	Nanostructure Initiator Mass Spectrometry: Tissue Imaging and Direct Biofluid Analysis. Analytical Chemistry, 2009, 81, 2969-2975.	6.5	117
36	Interaction of Cowpea Mosaic Virus (CPMV) Nanoparticles with Antigen Presenting Cells In Vitro and In Vivo. PLoS ONE, 2009, 4, e7981.	2.5	58

#	Article	IF	Citations
37	Viruses and nanotechnology. Preface. Current Topics in Microbiology and Immunology, 2009, 327, v-vi.	1.1	14
38	Siteâ€specific and Spatially Controlled Addressability of a New Viral Nanobuilding Block: <i>Sulfolobus islandicus</i> Rodâ€shaped Virus 2. Advanced Functional Materials, 2008, 18, 3478-3486.	14.9	54
39	Synthesis and Characterization of Iron Oxide Derivatized Mutant Cowpea Mosaic Virus Hybrid Nanoparticles. Advanced Materials, 2008, 20, 4816-4820.	21.0	17
40	Plasma Clearance of Bacteriophage QÎ² Particles as a Function of Surface Charge. Journal of the American Chemical Society, 2008, 130, 1328-1334.	13.7	105
41	Chemical Addressability of Ultraviolet-Inactivated Viral Nanoparticles (VNPs). PLoS ONE, 2008, 3, e3315.	2.5	25
42	Interaction between a 54-Kilodalton Mammalian Cell Surface Protein and Cowpea Mosaic Virus. Journal of Virology, 2007, 81, 1632-1640.	3.4	53
43	A Viral Nanoparticle with Dual Function as an Anthrax Antitoxin and Vaccine. PLoS Pathogens, 2007, 3, e142.	4.7	76
44	Microscale memory characteristics of virus-quantum dot hybrids. Applied Physics Letters, 2007, 90, 214104.	3.3	25
45	Amiodarone and Bepridil Inhibit Anthrax Toxin Entry into Host Cells. Antimicrobial Agents and Chemotherapy, 2007, 51, 2403-2411.	3.2	33
46	Viral MRI contrast agents: coordination of Gd by native virions and attachment of Gd complexes by azideâ€"alkyne cycloaddition. Chemical Communications, 2007, , 1269-1271.	4.1	187
47	Folic Acid-Mediated Targeting of Cowpea Mosaic Virus Particles to Tumor Cells. Chemistry and Biology, 2007, 14, 1152-1162.	6.0	213
48	Bio-distribution, toxicity and pathology of cowpea mosaic virus nanoparticles in vivo. Journal of Controlled Release, 2007, 120, 41-50.	9.9	229
49	Canine parvovirus-like particles, a novel nanomaterial for tumor targeting. Journal of Nanobiotechnology, 2006, 4, 2.	9.1	97
50	Viral nanoparticles as tools for intravital vascular imaging. Nature Medicine, 2006, 12, 354-360.	30.7	329
51	Virus-based nanoparticles (VNPs): Platform technologies for diagnostic imagingâ˜†. Advanced Drug Delivery Reviews, 2006, 58, 1505-1522.	13.7	268
52	Characterization of polymorphism displayed by the coat protein mutants of tomato bushy stunt virus. Virology, 2006, 349, 222-229.	2.4	38
53	Viruses and their uses in nanotechnology. Drug Development Research, 2006, 67, 23-41.	2.9	161
54	Anthrax Toxin Receptor 2â€"Dependent Lethal Toxin Killing In Vivo. PLoS Pathogens, 2006, 2, e111.	4.7	41

#	Article	IF	Citations
55	Organic and Inorganic Nanoparticle Hybrids. Langmuir, 2005, 21, 2098-2103.	3.5	72
56	Systemic trafficking of plant virus nanoparticles in mice via the oral route. Virology, 2005, 343, 224-235.	2.4	162
57	Why Provide an Opinions Section in PLoS Pathogens?. PLoS Pathogens, 2005, 1, e13.	4.7	0
58	A Soluble Receptor Decoy Protects Rats against Anthrax Lethal Toxin Challenge. Journal of Infectious Diseases, 2005, 192, 1047-1051.	4.0	89
59	Accelerated Bioorthogonal Conjugation:â€‰ A Practical Method for the Ligation of Diverse Functional Molecules to a Polyvalent Virus Scaffold. Bioconjugate Chemistry, 2005, 16, 1572-1579.	3.6	287
60	Decrease in Measles Virusâ€"Specific CD4 T Cell Memory in Vaccinated Subjects. Journal of Infectious Diseases, 2004, 190, 1387-1395.	4.0	59
61	Hybrid Virusâ^'Polymer Materials. 1. Synthesis and Properties of PEG-Decorated Cowpea Mosaic Virus. Biomacromolecules, 2003, 4, 472-476.	5.4	218
62	Measles Virus Infects and Suppresses Proliferation of T Lymphocytes from Transgenic Mice Bearing Human Signaling Lymphocytic Activation Molecule. Journal of Virology, 2003, 77, 3505-3515.	3.4	62
63	Novel Strategy for Inhibiting Viral Entry by Use of a Cellular Receptor-Plant Virus Chimera. Journal of Virology, 2002, 76, 4412-4419.	3.4	35
64	Targeting and Hematopoietic Suppression of Human CD34+ Cells by Measles Virus. Journal of Virology, 2002, 76, 6636-6642.	3.4	55
65	Disease model: dissecting the pathogenesis of the measles virus. Trends in Molecular Medicine, 2001, 7, 85-88.	6.7	13
66	Model Systems: Transgenic mouse models for measles pathogenesis. Trends in Microbiology, 2001, 9, 19-23.	7.7	35
67	CD46 as a Measles Receptor: Form Follows Function. Virology, 2000, 274, 5-10.	2.4	35
68	Dissecting Sites Important for Complement Regulatory Activity in Membrane Cofactor Protein (MCP;) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	3.4	126
69	Evasion of Host Defenses by Measles Virus: Wild-Type Measles Virus Infection Interferes with Induction of Alpha/Beta Interferon Production. Journal of Virology, 2000, 74, 7478-7484.	3.4	156
70	Clinical Isolates of Measles Virus Use CD46 as a Cellular Receptor. Journal of Virology, 2000, 74, 3967-3974.	3.4	123
71	Structural and Functional Studies of the Measles Virus Hemagglutinin: Identification of a Novel Site Required for CD46 Interaction. Virology, 1999, 256, 142-151.	2.4	38
72	Characterization of the inflammatory response during acute measles encephalitis in NSE-CD46 transgenic mice. Journal of Neuroimmunology, 1999, 96, 207-217.	2.3	58

#	Article	IF	Citations
73	Measles Virus Recognizes Its Receptor, CD46, via Two Distinct Binding Domains within SCR1-2. Virology, 1997, 233, 174-184.	2.4	63
74	A model of measles virusâ€“induced immunosuppression: Enhanced susceptibility of neonatal human PBLs. Nature Medicine, 1996, 2, 1250-1254.	30.7	31
75	Complete mutagenesis of the HIV-1 protease. Nature, 1989, 340, 397-400.	27.8	357